Genetically Modified MSCs For The Treatment Of GvHD

Graft-versus-host disease (GvHD) remains a significant challenge following allogeneic hematopoietic transplantation, with current mesenchymal stromal cell (MSC) therapies showing only moderate efficacy. Discover a next-generation strategy to boost the therapeutic potential of MSCs using genetic engineering.

This presentation dives into the development of adipose-derived MSCs (Ad-MSCs) that have been modified to co-express CXCR4 (a key migration molecule) and IL-10 (a potent anti-inflammatory cytokine). Learn how these modified cells—CXCR4-IL10-MSCs—demonstrated enhanced migration and superior immunomodulatory effects in vitro. Preclinical data from a xenogeneic GvHD mouse model showed that treatment significantly reduced disease severity, decreased pro-inflammatory responses, and increased regulatory cell populations compared to unmodified MSCs.

Additionally, see how this novel cell therapy transitioned from small-scale preclinical research to large-scale GMP production suitable for clinical trials, utilizing advanced cell culture technology.

Watch this on-demand webinar to understand the science and scale-up of this promising new approach.